(Total Views: 602)
Posted On: 11/23/2021 9:01:14 PM
Post# of 145875
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Quote:
Hey look. A 'mab' got BTD for Alzheimers.
Not great results. The secondary results don't support what was seen in the primary. Of course there's side effects, mainly cerebral swelling due to a leaky blood brain barrier.
Quote:
The change from baseline in the iADRS score at 76 weeks was −6.86 with donanemab and −10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P=0.04). The results for most secondary outcomes showed no substantial difference.
Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab.
https://www.nejm.org/doi/full/10.1056/NEJMoa2100708
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)